InVivoMAb Anti-Human ErbB2/Her2 Antibody (520C9) (HY286010)

Name: InVivoMAb Anti-Human ErbB2/Her2 Antibody (520C9)
Brand: abinScience
SKU: HY286010
Price: 370 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HY286010
Descripción	InVivoMAb Anti-Human CD340/ERBB2/HER2/NEU Antibody (520C9) [520C9] (HY286010) is a mouse monoclonal antibody detecting p185erbB2 in Blocking, ELISA. Suitable for Human.
Reactividad de especies	Human
Aplicaciones	Blocking, ELISA
Especie huésped	Mouse
Clonalidad	Monoclonal
Isotipo	IgG2a, kappa
ID de clon	520C9
Objetivo	CD340, EC:2.7.10.1, ERBB2, HER2, MLN 19, MLN19, Metastatic lymph node gene 19 protein, NEU, NGL, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2
Nivel de endotoxinas	< 1 EU/mg
Pureza	>95% as determined by SDS-PAGE.
Productos asociados	pH 7.4 Dilution Buffer
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P04626
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Fondo	Receptor tyrosine-protein kinase erbB-2 (CD340/ERBB2) is a ~137 kDa protein. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. CD340 is the therapeutic target of trastuzumab (Herceptin) and trastuzumab deruxtecan (Enhertu).
Nota	For research use only. Not suitable for clinical or therapeutic use.